Theriva Biologics Inc. (TOVX)
NYSE: TOVXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TOVX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.51M
- P/E (TTM)
- 0.10
- EPS (TTM)
- $1.15
- Dividend yield
- None
- 52-week range
- 0.12 – 0.49
- Day range
- 0.12 – 0.136
- Volume / Avg
- 1.24M / 2.02M
- Beta
- —
- Shares outstanding
- 45.89M
52-week range
TOVX stock today
Theriva Biologics (TOVX) closed at $0.12 on Nov 20, down 6.25% (-$0.008), versus the S&P 500's 3.70% decline. Shares are 75.5% below their 52-week high of $0.49, set on Apr 20, 2026 and 0.0% above the 52-week low of $0.12, near the bottom of the past year's range. TOVX is down 42.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.5%.
Theriva Biologics trades at 0.1x its trailing twelve-month earnings per share of $1.15.
Summary generated from market data by MetaCap's automated system. Methodology
About Theriva Biologics
Company profileTheriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Steven A. Shallcross CPA
- Headquarters
- Rockville, MD
- Employees
- 15
- Website
- therivabio.com
Financial highlights
Full financialsTheriva Biologics reported a net loss of $23.7 million, compared with a loss of $25.7 million a year earlier. Diluted earnings per share came in at -$2.08.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-23.74M | $-25.65M | $-18.35M | $-19.68M | $-14.27M |
| EPS (diluted) | $-2.08 | $-19.03 | $-28.48 | $-1.31 | $-1.90 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$2.50+1983.33%
- Strong buy 1
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.03 vs —
TOVX news
All TOVX news- Theriva™ Biologics anuncia una agrupación de accionesGlobeNewswire
- Theriva Biologics, Inc. Announces 1-for-30 Reverse Stock SplitNasdaq
- Theriva™ Biologics Announces Reverse Stock SplitGlobeNewswire
- Theriva Biologics, Inc. Stockholders Approve Authorized Share Increase to 500,000,000Nasdaq
- Theriva Biologics, Inc. Reports Third Quarter 2026 Results and SYN-004 Asset SaleNasdaq
- Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2026GlobeNewswire
- Theriva Biologics, Inc. Q3 Loss DropsNasdaq
- Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial ResultsGlobeNewswire
Theriva Biologics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| UPCUniverse Pharmaceuticals Inc. Class A | 1.08 | -20.59% | $5.43M | vs TOVX |
| LGVNLongeveron Inc. Class A | 1.66 | -8.79% | $5.60M | vs TOVX |
| TPSTTempest Therapeutics Inc. | 0.287 | -6.18% | $5.74M | vs TOVX |
| CNSPCNS Pharmaceuticals Inc. | 3.56 | -12.75% | $5.25M | vs TOVX |
| SNGXSoligenix Inc. | 0.2201 | -8.29% | $5.14M | vs TOVX |
| XCURExicure Inc. | 0.9001 | -12.82% | $5.89M | vs TOVX |
| ENVBEnveric Biosciences Inc. | 1.35 | -4.26% | $6.04M | vs TOVX |
| ADXNAddex Therapeutics Ltd ADR | 3.47 | +2.06% | $6.08M | vs TOVX |
Indexes, lists and sector
Theriva Biologics stock FAQ
What is Theriva Biologics's stock price today?
TOVX last traded at $0.12 as of Nov 20, 4:00 PM EST, down 6.25% on the day. Prices are delayed at least 15 minutes.
Does Theriva Biologics pay a dividend?
No. Theriva Biologics does not currently pay a regular cash dividend.
What is TOVX's P/E ratio?
TOVX trades at a trailing P/E ratio of 0.10.
Who is Theriva Biologics's CEO?
Mr. Steven A. Shallcross CPA is the chief executive officer of Theriva Biologics Inc., which has about 15 employees.
Has TOVX ever split its stock?
Yes. The most recent TOVX stock split was a 1-for-25 split on Aug 26, 2024, one of 4 splits on record.
What is the TOVX 52-week high?
The 52-week high for TOVX is $0.49 and the 52-week low is $0.12. The stock is currently 75.5% below its high.